FDA rejects the joint proposal by Johnson & Johnson's and Bayer AG to expand the use of blood thinner product Xarelto.
![FDA Rejects Proposal to Expand Use of Blood Thinner Xarelto FDA Rejects Proposal to Expand Use of Blood Thinner Xarelto](https://images.medindia.net/health-images/1200_1000/fda2.jpg)
J&J and Bayer conducted a joint study to test the effectiveness of the drug in preventing heart attacks and strokes and proposed to the FDA that it can be beneficial for patients suffering from acute coronary syndrome (ACS).
The FDA however has rejected the proposal and had said in January that while Xarelto can be an effective treatment option blood clots and stroke prevention, it cannot be used as maintenance or secondary prevention drug, adding that both J&J and Bayer have failed to conclusively prove that it can help heart attacks and strokes from recurring.
Source-Medindia